Galecto, Inc. (GLTO)
NASDAQ: GLTO · Real-Time Price · USD
29.66
-0.34 (-1.13%)
Feb 23, 2026, 4:00 PM EST - Market closed
Galecto Employees
Galecto had 5 employees as of December 31, 2024. The number of employees decreased by 8 or -61.54% compared to the previous year.
Employees
5
Change (1Y)
-8
Growth (1Y)
-61.54%
Revenue / Employee
n/a
Profits / Employee
-$3,168,800
Market Cap
1.79B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 5 | -8 | -61.54% |
| Dec 31, 2023 | 13 | -32 | -71.11% |
| Dec 31, 2022 | 45 | 5 | 12.50% |
| Dec 31, 2021 | 40 | 12 | 42.86% |
| Dec 31, 2020 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 800 |
| Agios Pharmaceuticals | 540 |
| MannKind | 407 |
| Nuvation Bio | 291 |
| Syndax Pharmaceuticals | 270 |
| Zymeworks | 263 |
| Aurinia Pharmaceuticals | 130 |
| Innoviva | 127 |
GLTO News
- 11 days ago - Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million - GlobeNewsWire
- 13 days ago - Galecto Announces Pricing of $275 Million Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - GLTO, MOVE: two penny stocks quadrupled today – but should you buy? - Invezz
- 3 months ago - Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029 - Benzinga
- 3 months ago - Galecto Announces Acquisition of Damora Therapeutics - GlobeNewsWire
- 3 months ago - Galecto Reports Third Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 4 months ago - What's Going On With Nano-Cap Galecto Stock On Tuesday? - Benzinga